|
PERSONALIZE: 
Overlook
at Great Notch 150 Clove Road Little Falls, New Jersey 07424 Telephone: (973) 890-8988 Fax: (973) 890-8866 
|
Main | Order CD-ROM | Faculty | Learning Objectives
Agenda | CME/CE | Disclosure | Technical Requirements
You may also be interested in The Advanced Certificate Program: Breast Cancer Management. This yearlong CME/CE program offers clinicians current cutting-edge information targeting the management of breast cancer. Learn more... or You may be interested in the 2006 webcast... "Keeping Pace with Targeted Therapies in Breast Cancer: Highlights from the 2006 ASCO Annual Meeting" Dear Colleague: Presentations given at the 2005 American Society of Clinical Oncology (ASCO) annual meeting on the dramatic benefits of biologics in patients with breast cancer have sparked high levels of optimism about a new era in breast cancer treatment. Because biologics are administered in combination with chemotherapy, new approaches in this realm of treatment are critical. Burgeoning research on aromatase inhibitors also provides guidance on the optimal initiation of this treatment and the identification and minimization of related adverse drug risks. This year more than 200,000 women will be diagnosed with breast cancer in the United States, while more than 40,000 deaths will be attributed to the disease. Appropriate treatment, especially in the early stages of breast cancer, is paramount to preventing recurrence and sustaining life expectancy. As options for treatment increase, healthcare practitioners need to make astute recommendations about the use of biologics and other anticancer drug regimens. In ASCO 2005: Paradigm Shift in Breast Cancer Treatment, authorities in breast cancer will address some of your most important concerns regarding progress in endocrine therapy and chemotherapies, and pioneering developments in biologic therapy. The presentation also includes an insightful overview on management and monitoring of patients on emerging therapies. It is sure to be an informative and valuable webcast. Sincerely, ChairHarold J. Burstein, MD, PhD Department of Oncology Dana-Farber Cancer Institute Assistant Professor of Medicine Harvard Medical School Boston, Massachusetts
Activity Agenda Role of Hormone Therapy and New Antiangiogenic Agents in Breast Cancer Regimens How are Chemotherapeutic and Anti-HER2 Receptor Agents Affecting Therapeutic Strategies in Breast Cancer? Management and Monitoring of Patients on Emerging Therapies top Target Audience This activity is designed for medical directors, pharmacy directors, and nurse case managers who care for patients with breast cancer. Activity Goal The goal of this professional education activity is to review treatment options for patients with breast cancer. At the completion of this activity, participants should be able to:
Statement of Accreditation Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 contact hour. Provider #00012705. Statement of Accreditation: PHARMACISTS Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  This activity has been planned and implemented in accordance Contract for Mutual Responsibility in CME/CE Projects In Knowledge has developed the Contract for Mutual Responsibility in CME/CE to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.For more information on the Contract for Mutual Responsibility in CME/CE, please click here. Disclosure Information The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Updated Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Harold J. Burstein, MD, PhD, has received grant/research support from and is on the speakers bureau of Genentech, Inc. Dr. Burstein has disclosed that he will reference the unlabeled or unapproved use of Phase III data on trastuzumab. Maura N. Dickler, MD, has received grant/research support from Genentech, Inc, Novartis Pharmaceuticals Corporation, and Pfizer Inc; is a consultant for AstraZeneca Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Pfizer Inc; is on the speakers bureau of AstraZeneca Pharmaceuticals and Pfizer Inc; and is on the advisory board of AstraZeneca Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Pfizer Inc. Dr. Dickler has disclosed that she will reference the unlabeled or unapproved use of bevacizumab and trastuzumab. Kristen Fessele, RN, MSN, APN-C, AOCN, has disclosed no significant relationships. Ms. Fessele has disclosed that she will reference the unlabeled/unapproved use of bevacizumab in metastatic breast cancer and trastuzumab in the nonmetastatic setting. Michele Frank-Bazer, RN, MS, AOCN, has disclosed that she is on the speakers bureau of Abraxix Oncology. Ms. Frank-Bazer has disclosed that she will reference unlabeled/unapproved uses of drugs or products in the presentation. Jennifer Ligibel, MD, has disclosed that she is on the Advisory Board for Genentech, Inc. Dr. Ligibel has disclosed that she will not reference unlabeled/unapproved uses of drugs or products in the presentation. Peer Reviewer has disclosed no significant relationships. Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient. This independent CME/CE activity is supported by an educational grant from Genentech, Inc. top |
